Melior Discovery
1 known investors
Find your way into Melior Discovery
638 people in our graph share verified history with the Melior Discovery team — schools, employers, funds. One of them is your warm intro.
Ben Lererunlockedknows Andrew Reaume · together at University of Pennsylvania (overlapped)
×3knows the team · via The Wharton School
×4knows the team · via University of Pennsylvania
×4knows the team · via University of Connecticut
Melior Discovery provides in vivo pharmacology services and phenotypic screening platforms for pharmaceutical and biopharmaceutical companies to evaluate candidate therapeutics in animal disease models. The company operates proprietary technology including theraTRACE® to identify new therapeutic potential and support drug development and repositioning.
Founders & leadership
AR
Andrew ReaumeinPresident and CEO, Co-FounderAndrew Reaume is co-founder and president/CEO of Melior Discovery, which provides in vivo pharmacology services and phenotypic screening platforms for drug discovery and development. He has more than 20 years of experience in pharmaceutical research, including roles at multinational pharma companies and biotech firms.
AR
Andrew Reaume, PhD, MBAPresident and CEO, Co-Founder
Investors · 1
In the news
Frequently asked questions
- What does Melior Discovery do?
- Melior Discovery provides in vivo pharmacology services and phenotypic screening platforms for pharmaceutical and biopharmaceutical companies to evaluate candidate therapeutics in animal disease models. The company operates proprietary technology including theraTRACE® to identify new therapeutic potential and support drug development and repositioning.
- Who founded Melior Discovery?
- Melior Discovery was founded by Andrew Reaume, Andrew Reaume, PhD, MBA.
- Who are Melior Discovery's investors?
- Melior Discovery's investors include BioAdvance.